Sanofi to Continue Development of Kadmon’s dcSSc Therapy After Buyout
Sanofi has entered into a merger agreement with Kadmon, which is developing belumosudil (KD025), an oral investigational treatment for people with the diffuse cutaneous form of systemic sclerosis (dcSSc). Belumosudil, sold under the brand name Rezurock, was recently approved for patients, 12 years and older, with chronic…